Investing in Cures for Cancer: GE Poised to Lead Industrialization of Cell Therapy Industry with Acquisition of Biosafe Group SA
GE Healthcare has acquired Biosafe Group SA, a supplier of integrated cell bioprocessing systems for the rapidly growing cell therapy and regenerative medicine industry for an undisclosed sum. The acquisition of Biosafe expands GE Healthcare’s end-to-end ecosystem of products, solutions and services for our cell therapy customers, and expands GE’s technology reach to a number of new cell and therapy types.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160713005783/en/
Cellular therapies are rapidly changing the healthcare landscape by providing life-saving and potentially curative treatments for many of the world’s most challenging diseases, especially cancer. The cell therapy oncology market alone is expected to reach $30 billion by 20301 with more than 600 potentially life-changing therapies in clinical trials at the end of 20152.
Biosafe, headquartered in the Lake Geneva region in Switzerland, with a global presence, has a 20 year track-record in automated cell processing and is a recognized leader in the field with reliable applications in bioprocessing, regenerative medicine and stem cell banking. Its proprietary products offer significant advantages over conventional processing tools, with closed fluid pathways, built-in traceability and single-use consumables. The strong strategic fit and complementary business models of GE Healthcare’s Life Sciences business and Biosafe combined with expanded capabilities in product development and commercial reach, will offer significant customer and ultimately patient benefits.
Kieran Murphy, CEO Life Sciences, GE Healthcare said: “GE is building a world-class set of tools, technologies and services for cell and gene therapy and Biosafe’s expertise and innovative systems will strongly enhance our customer offering. GE and Biosafe share a vision of an integrated approach to helping customers optimize every stage of their process to reduce production risks dramatically and increase access to these remarkable new medicines.”
Claude Fell, Founder and Chairman, Biosafe Group SA, said: “Together with GE we will have the combination of biological, engineering and industrial capabilities to help accelerate the fields of cell therapy and cellular immunotherapy into the mainstream, benefitting patients globally, and bringing the vision of personalized medicine to reality.” Olivier Waridel, Biosafe CEO, who will continue to lead Biosafe within the new integrated GEHC structure, added: “Joining GE Healthcare will give Biosafe an outstanding opportunity to couple its unique cell processing technology with GE Healthcare’s strong, global infrastructure, leading to improved capabilities for our customers and enhanced market penetration.”
GE’s strategy is to work with the industry and partners to develop a digitally-enabled ecosystem of complete tools, solutions and services for cell therapy aimed at accelerating the standardization, collaboration and integration customers need to bring these new therapies into mainstream clinical practice. GE has engaged globally with leaders in the industry, such as Canada’s Center for the Commercialization of Regenerative Medicine, the UK’s Cell and Gene Therapy Catapult, Australia’s Cell Therapy Manufacturing Cooperative Research Centre and leading clinical centers such as UPenn, Karolinska Institute, Memorial Sloan-Kettering and Mayo Clinic.
In 2016, GE has announced further significant investments in the cell therapy and regenerative medicine space. In April, GE Ventures and Mayo Clinic announced the launch of Vitruvian Networks, Inc., an independent platform company committed to accelerating access to cell and gene therapies through advanced, cloud-ready software systems and manufacturing services. In January, GE announced the BridGE@CCRM Cell Therapy Centre of Excellence, a US $31.5 million co-investment with the Canadian Government to promote new technologies for the production of cellular therapies in Toronto.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
About Biosafe Group SA
Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and São Paulo) and is present in more than 50 countries, either directly or through distributors. For more information about Biosafe, visit the website www.biosafe.ch.
2 Alliance for Regenerative Medicine Q1 Data Report 2016 http://alliancerm.org/page/arm-data-reports#
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage22.2.2018 06:00 | Pressemelding
Ferring Pharmaceuticals and MSD, known as Merck & Co., Inc., Kenilworth, N.J., U.S.A., through its MSD for Mothers initiative, today announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program (HRP) at the World Health Organization (WHO). CHAMPION is investigating whether Ferring’s proprietary and heat-stable carbetocin could offer a new solution to prevent excessive bleeding after childbirth (postpartum haemorrhage or PPH).2,3 Involving nearly 30,000 women in 10 countries, it is the largest clinical trial ever conducted in PPH.2,3 This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221006496/en/ Each year, 14 million mothers are affected by PPH.4 As the leading direct cause of maternal mortality, 480,000 mothers died from PPH between 2003-09.1 Even when women survive, PPH can result in the need for serious medical interventions, including surgica
The Nippon Foundation: Project to Map Ocean Floor by 2030 Now Operational22.2.2018 05:00 | Pressemelding
The Nippon Foundation Chairman Yohei Sasakawa announced at a press conference today that The Nippon Foundation – GEBCO Seabed 2030 Project is now operational. The Project will realize Mr. Sasakawa’s vision of mapping the entire ocean floor by 2030. The Nippon Foundation has pledged US$2 million annually, and is calling for additional support from the global ocean community. Mr. Sasakawa noted, “The Nippon Foundation alone cannot achieve the objectives of this ambitious project. We will need the support of diverse stakeholders, including maritime corporations and technical experts. It is crucial that the ocean community comes together to achieve this goal”. He was joined by leading ocean-mapping experts, who emphasized that understanding the bathymetry of the global ocean is imperative for improving maritime navigation, and also for enhancing our ability to predict climate change and monitor marine biodiversity and resources. A comprehensive map of the seafloor will assist global effort
Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis21.2.2018 21:01 | Pressemelding
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1) at week four of treatment. The study is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment. “Our goal is to bring the best triple combination to patients as rapidly as possible, and this first Phase 3 study of VX-659 in combination with tezacaftor and ivacaftor is a significant step toward that goal,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical
Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series21.2.2018 18:00 | Pressemelding
ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 µm CO2 lasers and 1.06 µm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005364/en/ The ULTRA 9MW offers MultiWave processing of thin materials. (Photo: Business Wire) The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized
Luxoft One of Six Companies Collaborating with Amazon Web Services to Accelerate Blockchain Adoption21.2.2018 16:30 | Pressemelding
Luxoft Holding Inc (NYSE:LXFT), a global IT service provider, announces today that it is collaborating with Amazon Web Services (AWS) to enable corporates to adopt blockchain and Distributed Ledger Technologies (DLT). Luxoft is one of six IT and consulting services companies to make its blockchain advisory and development services available to AWS users. “We are very excited to be working with AWS to help users engage with blockchain and DLTs,” said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. “Blockchain is about removing data silos, improving trust and operational efficiencies. By using AWS to deploy and integrate DLTs into day-to-day processes, businesses can revolutionize how they operate.” Luxoft helps accelerate the deployment and integration of blockchain and DLT-based projects on AWS and is already working on a number of DLT projects using the cloud. For example, Luxoft is building a healthcare claims processing system for a leading healthcare provider usin
Westinghouse Electric Company to Provide Engineering Support at Vandellós 1 in Partnership with EDF21.2.2018 16:30 | Pressemelding
Westinghouse Electric Company and Electricité de France (EDF), in partnership, announced today that they have been awarded a contract from Empresa Nacional de Residuos Radiactivos (ENRESA), the Spanish agency responsible for radioactive waste management and nuclear plant decommissioning. The agreement covers a four-year engineering support contract for the latency phase of the dismantling and decommissioning project at Vandellós I Nuclear Power Station in Spain and includes the preparation of technical and licensing documentation. “We are extremely pleased that ENRESA has selected Westinghouse and EDF to continue supporting the decommissioning activities at Vandellós I Nuclear Power Station,” said Yves Brachet, Westinghouse vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “This contract further demonstrates Westinghouse’s global capabilities and expertise in providing innovative decommissioning solutions.” Sylvain Granger, head of EDF's decommi